Morgan Stanley raised the firm's price target on Disc Medicine to $85 from $80 and keeps an Overweight rating on the shares after the company hosted a call to review the recent updated data for selcodebart presented at ASCO and EHA. The firm has raised its view of the odds of success for selcodebart to 50% from 40% and adjusted its market model to include both the non-transfusion-dependent and transfusion-dependent patients, instead of limiting it to the nTD population, the analyst tells investors.
